Table 5.
Validity of the applied questionnaires for assessment of OHRQoL in patients with rheumatoid diseases.
| Disease | Questionnaire | ICC | Crohnbach’s α | Further Results |
|---|---|---|---|---|
| SSc [19] | OHIP 49 | 0.84 (t0–3 mo), 0.69 (3 mo–6 mo) | n/a | SEM 12.05 (t0–3 mo), 18.34 (3 mo–6 mo) |
| SSc [19] | OHIP 14 | 0.82 (t0–3 mo), 0.61 (3 mo–6 mo) | n/a | SEM 4.07 (t0–3 mo), 6.09 (3 mo–6 mo) |
| SSc [10] | MHISS | 0.93 | 0.99 | n/a |
| SS [28] | OHIP 14 | 0.94 | 0.89 | n/a |
| SS [29] | OHIP 14 | n/a | n/a | SEM: 3.3 or 4.0 depending on intervention |
| BD [30] | OHIP 14 | n/a | 0.92 | Test–retest correlation 0.64–0.79 |
| BD [30] | OHRQoL questionnaire | n/a | 0.93 | Test–retest correlation 0.67–0.99 |
| BD [31] | OHIP 14 | n/a | 0.91 (active), 0.93 (inactive) | n/a |
| BD [32] | OHIP 14 | n/a | 0.95 (UK) and 0.93 (Turkey) | n/a |
OHIP: Oral Health Impact Profile; OHRQoL: oral-health-related quality of life; ICC: intraclass correlation; SEM: standard eroor of measurement; UK: United Kingdom; SSc: systemic sclerosis; SS: Sjörgen syndrome; BD: Behcet’s disease; mo: month.